Close

2015 Expected to be 'Transformative' Year for Applied Genetic Technologies (AGTC) - Roth Capital

February 11, 2015 11:39 AM EST Send to a Friend
Roth Capital affirms Applied Genetic Technologies (Nasdaq: AGTC) at Buy with a price target of $34 following Q215 results issued ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login